Retrospective and Analytical Study of the Doctrine Related Pharmaceutical Polymorphism and Patents
DOI:
https://doi.org/10.56511/JIPBS.2015.v2.i04.pp579-595Abstract
Called pharmaceutical polymorphism to change of the crystal structure of a substance when it is in its solid state, this has generated a controversy over whether or not to enjoy protection for patents for invention, and that it could limit or delay the access of generic drugs to health care centers, or services, this study aims to define the main technical characteristics of pharmaceutical polymorphs and determine its patentability under Costa Rican law, such legislation also compared with the doctrine poured into other countries, mainly the United States of America. Methodology: Written information sources and electronic media since 1850 to February 2014 were revised, data were collected and information was placed in an instrument that selects the main themes. Then it was analyzed by triangulation and conclusions were made by technical and legal criteria. Results: Among the main results the eligibility of patentable matter was determined against the non-patentable, the main technical criteria of pharmaceutical polymorphs for a prior art study were established and the differences between the US and Costa Rican law doctrine on the subject of polymorphism and patents was determined
Keywords:
Drugs, Patents,, Pharmacy, Pharmaceutical polymorphism, physicochemical propertiesDownloads
References
C abanellas de las Cuevas, Guillermo: Derechos de las Patente s de Invención (Rights Patents) . 2nd Editión. Buenos Aires: Heliasta,pp 1 - 30, 2004.
World Intellectual Property Organization. Understanding Industrial Property. s.l.:, 2008.World Intellectual Property Organization. https://www.google.com/ url?sa=t&rct=j&q=&esrc=s&source=web& cd=1&cad=rja&uact=8&ved=0CB0QFjAAa hUKEwjx89HqntnIAhXD6SYKHck_CCk&ur l=http%3A%2F%2Fwww.wipo.int%2Fed ocs%2Fpubdocs%2Fen%2Fintproperty% 2F895%2Fwipo_pub_895.pdf&usg=AFQjC NHlNkiaruFK9NP5URxEVBJTH5nHQw&si g2=em30lOCf2eZVk1QDt_6MSw
Brittain, H.: Polymorphism and solvatomorphism 2006. Journal of Pharmaceutical Scienses, 2008; 97(9): 3611-3636.
Pan American Health Organization. Aspects of Intellectual Property Rights Related to Trade(ADPIC)and Access to Medicines. Managua: Pan American Health Organization. 2004.
Madrigal Redondo, German Leonardo: Analysis of the criteria of experts on potential economic effects of the phenomenon of polymorphism of drug substances patent of invention in Costa Rica. and its application for monitoring of technological systematization of local pharmaceutical industry. Revista CENIC Ciencias Biologicas 2010; No 41: 2010 ISSN 0253-5688.
Lerma, L.: Patentabilidad de los Compuestos Polimórficos (Patentability of polymorphic compounds), Universidad Peruana Cayetano Heredia. Recovered November 10, 2008, from: www. indecopi.gob.pe/ ArchivosPortal/boletines/recompi/castella no/articulos/primavera2007/LERMA.pdf.
Brittain, H. : Polymorphism in pharmaceutical solids. Boca Ratón, United States of America: Editorial Marcel Dekker 1999.
Carstensen, J. : Advanced pharmaceutical solids. Boca Ratón Florida, United States of America: Marcel Dekker Inc. 2001.
Martín, A., y Molina, E.: Polimorfismo farmacéutico. Offarm, 2006; 25 (8): 94100.
Sanz Pedrero, P.: Fisicoquímica para farmacia y biología (Physical chemistry and biology to pharmacy). Madrid, España: Editorial Masson. 1994.
Hilfiker, R.: Polymorphism in the pharmaceutical industry. Londres, Inglaterra: Editorial WILEY-VCH Verlag GmbH y Co. KgaA. 2006
Brittain, H. : Polymorphism and solvatomorphism. Journal of Pharmaceutical Scienses, 2007; 96(4): 706727.
World Trade Organization. Agreements on intellectual property rights and trade. Punta del Este, Uruguay: World Trade Organization 1996.
Costa Rica,Procurator General of the Republic, Costa Rican Legal Information System.. (2008). Law No 6867 Law of patents, industrial designs, and utility models.Recuperado el 30 de julio de 2009, de: http://www.pgr.go.cr/scij.
United States of America, Congress of the United States of America Federal Code section 101, Patents 2013.
Cuba, Consejo de Estado (2012) Gaceta Oficial No 2; Decreto Ley 290 Patentes de Invención.
European Union, European Patent Convention (2000) displayed in https://www.oepm.es/es/propiedad_indu strial/Normativa/normas_sobre_proteccio n_de_invenciones/Derecho_europeo_de_p atentes/
Argentina, National Congress (1996) Law Nº 24.481Law of Patents and Utility Models. Visualized http://www.infoleg. gov.ar/infolegInternet/anexos/250009999/27289/norma.htm
México, Congreso de la Estados Unidos Mexicanos (1992) Ley Propiedad Industrial visualizado en: http://www.sice.oas.org/int_prop/nat_leg/ Mexico/lipmexsa.asp .
Brasil, Consejo Federal Senado República Federal de Brasil (1997) Ley Nº 9.279 visualizado. en: http://www.wipo.int/ wipolex/es/details.jsp?id=515 .
Piatti, S. : Criteria for analysis of patents. recovered. Recuperado el 10 de november, 2008, de: www.deolhonaspatentes.org.br/media/fil e/Publicacoes/criterios_analisispatentes.p df.
Bernstein J: Crystal structure prediction and polymorphism ACA Transactions 2004; 39, 14-23.
Anonimus (2014) Crystalline basic structures visualized in http://cienciasdelosmaterialesindustrial.b logspot.com/2013/05/describir-laestructura-cristalina-de.htm .
Madrigal G, Vargas R, Carazo G, Ramírez N, :Determination and identification of two crystalline polymorphic forms of clopidogrel bisulfate in pharmaceutical raw materials Lecture XI Congress of the Cuban Society of Pharmaceutical Sciences 2012. pp 515-520.
Madrigal Redondo, German Leonardo.: Analysis of expert judgment on the possible effects of the phenomenon of polymorphism Socioeconomic medicaments in the Field of Patents in Costa Rica. San José: Universidad Estatal a Distancia Analysis of expert judgment on the possible effects of the phenomenon of polymorphism Socioeconomic medicaments in the Field of Patents in Costa Rica 2011.
Bernstein, J. : Polymorphism and patents from a chemist’s point of view en Polymorphism in the polymorphism in the pharmaceutical industry. Londres, Inglaterra : Editorial WILEY-VCH Verlag GmbH & Co. KgaA 2008.
Barnes, R. D., Wood-Kaczmar, M. W., Curzons, A., Lynch, I. R., Richardson, J. E., y Buxto, P. C.:US Patent No 4,721,723; United States of America. Retrieved on July 30, 2009, de: http://patft.uspto.gov/netacgi/ nph Parser?Sect1=PTO1&Sect2=HITOFF &d=PALL&p=1&u=%2Fnetahtml%2FPTO %2Fsrchnum.htm&r=1&f=G&l=50&s1=47 21723.PN.&OS=PN/4721723&RS=PN/472 1723.
Christensen, J. A., Squires, y Felt, R. (1978). US Patent No 4,007, 196. United States of America. Retrieved on July 30, 2009, de: http://patft. Uspto.gov/netacgi/nph Parser?Sect1=PTO1&Sect2=HITOFF&d=P ALL&p=1&u=%2Fnetahtml%2FPTO%2Fs rchnum.htm&r=1&f=G&l=50&s1=400719 6.PN.&OS=PN/4007196&RS=PN/4007196
Crookes, D. L. (1985). US Patent No 4,521,431. United States of America. Retrieved on July 30, 2009 l de: http://patft.uspto.gov/netacgi/nphParser?Sect1=PTO1&Sect2=HITOFF&d=P ALL&p=1&u=%2Fnetahtml%2FPTO%2Fs rchnum.htm&r=1&f=G&l=50&s1=452143 1.PN.&OS=PN/4521431&RS=PN/4521431
Price, B. J., Clitherow, J. W., y Bradshaw, J. (1978). US Patent No. 4,128,658. United States of America. Retrieved on July 30, 2009. , de:http://patft.uspto.gov/netacgi/nphPar ser?Sect1=PTO1&Sect2=HITOFF&d=PALL &p=1&u=%2Fnetahtml%2FPTO%2Fsrchn um.htm&r=1&f=G&l=50&s1=4128658.PN. &OS=PN/4128658&RS=PN/4128658.
Tampa diez del Corral, A., Bosch Llado, J., Molins Grau, E., y Onrubia Miguel, M. D. (2000). Patent No. WO/2000/001693. United States of America. Retrieved on July 30, 2009, de: http://www.wipo.int/ pctdb/en/wo.jsp?wo=2000001693.
Tellekson, D., Richadrson, E., y Lee, S. :Strategic of attacking and defending pharmaceutical patents. A modern take on the art of war intellectual property. Technology and Law Journal,2005; 17(12): 105-110.
Costa Rica National Register of Property (2010) Basis Data Application Patent Nullity Procedures No 2637 Crystalline forms of 2-methyl-thieno benzodiazepine
Yuki Kimura, Hiromasa Niinomi, Katsuo Tsukamoto, Juan M. García-Ruiz : In-situ Live Observation of Nucleation and Dissolution of Sodium Chlorate Nanoparticles by Transmission Electron Microscopy 2014. dx.doi.org/10.1021/ja412111f J. Am. Chem. Soc. En linea.
United States of America, Food and Drug Administration CDER, F. F. (2007). Guidance for industry ANDAs: pharmaceutical solid polymorphism chemistry, manufacturing, and controls information. Washington, United States of America: Food and Drug Administration.RecoveredJuly 30, 2009, from: http://www.fda.gov/Drugs /Res ourcesForYou/Industry/default.htm.
Published
How to Cite
Issue
Section
Copyright (c) 2015 German L Madrigal Redondo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at